SCHEMBL19806043

SCHEMBL19806043

CC(C)(C)c1cccc(CC(C)(C)c2ccc3cc(Cl)ccc3c2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR9 P51686 2/20 0.49
CYP2A6 P11509 1/20 0.37
P2RX1 P51575 1/20 0.35
MAOB P27338 3/20 0.35
KIF11 P52732 1/20 0.34
HTT P42858 2/20 0.34
HPGD P15428 2/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
PPARG P37231 1/20 0.33
PPARA Q07869 1/20 0.33
PKM P14618 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
KCNH2 Q12809 1/20 0.33
ESR1 P03372 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22761971 0.86 CCR9 (0.42) CCR9P2RX1KIF11PKMCYP3A4
SCHEMBL19806133 0.85 CCR9 (0.45) CCR9CYP2A6HTTSLC6A2SLC6A4
SCHEMBL15070880 0.79 CYP2A6 (0.50) CCR9CYP2A6P2RX1HTTHPGD
SCHEMBL21094294 0.77 CCR9 (0.37) CCR9KIF11PKMESR1ESR2
SCHEMBL22414493 0.76 PNMT (0.38) CCR9KIF11PKMCYP3A4LMNA
SCHEMBL20802198 0.75 LMNA (0.42) MAOBKIF11HTTALDH1A1TDP1
SCHEMBL23483734 0.74 ESR1 (0.41) KIF11HTTKCNH2ESR1ESR2
SCHEMBL19250259 0.74 ESR1 (0.62) HPGDALDH1A1TDP1CYP3A4SLC6A2
SCHEMBL18812974 0.74 HTR2A (0.50) MAOBKIF11KDM4EALDH1A1SLC6A4
SCHEMBL23479360 0.74 CYP2A6 (0.48) CCR9CYP2A6P2RX1HTTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202354-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-02-12 US disclosed
US-20180022707-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2018-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180022707-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF KDM1B, KDM6B, KDM2B CCR9 4393/4885CYP2A6 2951/4885P2RX1 3622/4885
US-10202354-B2 Therapeutic compounds and uses thereof KDM1B, KDM6B, KDM2B CCR9 4393/4885CYP2A6 2951/4885P2RX1 3622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.